AU2002236572A1 - Methods for detecting the efficacy of anticancer treatments - Google Patents

Methods for detecting the efficacy of anticancer treatments

Info

Publication number
AU2002236572A1
AU2002236572A1 AU2002236572A AU3657202A AU2002236572A1 AU 2002236572 A1 AU2002236572 A1 AU 2002236572A1 AU 2002236572 A AU2002236572 A AU 2002236572A AU 3657202 A AU3657202 A AU 3657202A AU 2002236572 A1 AU2002236572 A1 AU 2002236572A1
Authority
AU
Australia
Prior art keywords
growth factor
factor receptor
receptor
antibody
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002236572A
Other languages
English (en)
Inventor
Corazon D. Bucana
Isaiah J Fidler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of AU2002236572A1 publication Critical patent/AU2002236572A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2002236572A 2000-11-03 2001-11-02 Methods for detecting the efficacy of anticancer treatments Abandoned AU2002236572A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24574500P 2000-11-03 2000-11-03
US60/245,745 2000-11-03
PCT/US2001/046937 WO2002039121A2 (en) 2000-11-03 2001-11-02 Methods for detecting the efficacy of anticancer treatments

Publications (1)

Publication Number Publication Date
AU2002236572A1 true AU2002236572A1 (en) 2002-05-21

Family

ID=22927911

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002236572A Abandoned AU2002236572A1 (en) 2000-11-03 2001-11-02 Methods for detecting the efficacy of anticancer treatments

Country Status (6)

Country Link
US (1) US7344829B2 (de)
EP (1) EP1332368A2 (de)
JP (1) JP2004529315A (de)
AU (1) AU2002236572A1 (de)
CA (1) CA2427622A1 (de)
WO (1) WO2002039121A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1441736A2 (de) * 2001-10-29 2004-08-04 Novartis AG Verwendung von 7h-pyrrolo[2,3-d]pyrimidinderivaten in der behandlung solider tumore
KR101086533B1 (ko) * 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
AU2003286004A1 (en) * 2002-11-08 2004-06-07 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
WO2004041865A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
ES2466716T3 (es) * 2002-11-08 2014-06-11 Ablynx N.V. Anticuerpos de un solo dominio estabilizados
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
SI2055786T1 (sl) * 2002-11-27 2011-04-29 Sugen Inc Fosfospecifična PAK-protitelesa in diagnostični kompleti
EP2251357A1 (de) * 2003-11-07 2010-11-17 Ablynx N.V. Camelidae schweren Ketten Antikörpern VHHS gegen Epidermal Growth Faktor Rezeptor (EGFR) und Ihre Verwendungen
ATE514783T1 (de) 2003-11-12 2011-07-15 Schering Corp Plasmidsystem zur expression mehrerer gene
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
MXPA06014015A (es) * 2004-06-03 2007-02-08 Hoffmann La Roche Tratamiento con gemcitabina y un inhibidor del receptor del factor de crecimiento epidermico.
RU2006146612A (ru) 2004-06-03 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Лечение цисплатином и ингибитором рецептора эпидермального фактора роста (egfr)
MX2007006640A (es) * 2004-12-03 2007-06-19 Schering Corp Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina.
EP1879587A2 (de) * 2005-04-15 2008-01-23 Schering Corporation Verfahren und zusammensetzungen zur behandlung oder vorbeugung von krebs
AU2006259536A1 (en) * 2005-06-15 2006-12-28 Schering Corporation Anti-IGF1R antibody formulations
GB2437250C (en) * 2006-04-18 2012-08-15 Iti Scotland Ltd Method and system for monitoring the condition of livestock
US20100291592A1 (en) * 2006-04-20 2010-11-18 Taro Semba Novel marker for sensitivity against sulfonamide compound
WO2008102495A1 (ja) * 2007-02-22 2008-08-28 Banyu Pharmaceutical Co., Ltd. Mark4に作用する化合物の評価方法
US20090286263A1 (en) * 2008-03-05 2009-11-19 United States Army As Represented By The Secretary Of The Army Skin tape stripping: a non-invasive diagnostic strategy for dermal exposure to cytotoxic compounds
US8778331B2 (en) * 2008-06-30 2014-07-15 Medical Diagnostic Laboratories, Llc Method of determining susceptibility of a tumor cell to a chemotherapeutic agent: novel use of herpes simplex virus
WO2010030325A1 (en) * 2008-09-09 2010-03-18 Albert Einstein College Of Medicine Of Yeshiva University Methods for increasing efficacy of radioimmunotherapy of melanoma
BR122018013284B1 (pt) 2008-10-29 2022-03-03 Ablynx N.V Formulações de moléculas de ligação ao antígeno de domínio único, seu método de formulação e seu uso, kit ou artigo de fabricação, bem como método para preparar uma formulação reconstituída contendo uma molécula de sdab
AU2009314311B2 (en) * 2008-10-29 2013-01-10 Ablynx N.V. Methods for purification of single domain antigen binding molecules
US20110104719A1 (en) * 2009-11-02 2011-05-05 Aletta John M Methylarginine detection in cells and tissues
DK2706988T3 (da) 2011-05-12 2020-01-20 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Liposomer omfattende polymer konjugerede lipider og relateret brug
KR20210050326A (ko) * 2019-10-28 2021-05-07 삼성전자주식회사 유기금속 화합물, 이를 포함한 유기 발광 소자 및 이를 포함한 진단용 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68921918T2 (de) * 1988-05-09 1995-09-07 Univ Temple Verfahren zur Voraussage der Wirksamkeit einer antineoplastichen Behandlung bei einzelnen Patienten.
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
CA2106862A1 (en) * 1991-03-27 1992-09-28 Robert M. Lavker Method of indentifying and modulating the activity of label retaining cells for diagnostic and therapeutic purposes
CA2117913C (en) * 1992-04-10 2006-05-09 Richard J. Epstein Activation-state-specific phosphoprotein immunodetection

Also Published As

Publication number Publication date
JP2004529315A (ja) 2004-09-24
US7344829B2 (en) 2008-03-18
US20020132275A1 (en) 2002-09-19
CA2427622A1 (en) 2002-05-16
WO2002039121A3 (en) 2002-09-06
EP1332368A2 (de) 2003-08-06
WO2002039121A2 (en) 2002-05-16

Similar Documents

Publication Publication Date Title
US7344829B2 (en) Methods for detecting the efficacy of anticancer treatments
ES2541925T3 (es) Métodos y composiciones para el uso diagnóstico en pacientes de cáncer
Ikeda et al. Prognostic significance of angiogenesis in human pancreatic cancer
Mukaida et al. Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer
AU2014312079B2 (en) Diagnostic methods and compositions for treatment of glioblastoma
McKeever et al. A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters
US20080226646A1 (en) Use of biomolecular targets in the treatment and visualization of tumors
McKeever et al. MIB-1 proliferation index predicts survival among patients with grade II astrocytoma
Yardley et al. Panitumumab, gemcitabine, and carboplatin as treatment for women with metastatic triple-negative breast cancer: a Sarah Cannon Research Institute phase II trial
WO2005094332A2 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators in non-small cell lung cancer
Yang et al. Chemokine receptor CXCR4 and its ligand CXCL12 expressions and clinical significance in bladder cancer
KR101928618B1 (ko) Tk1 단백질의 발현이 항진된 결장직장암 환자에 대한 치료효과 예측 방법
Hatori et al. Midkine expression in human periapical granulomas
Häggström et al. Castration‐induced reduction of vascular endothelial growth factor expression in benign human prostate tissue is lost in advanced prostate cancer
KR20200106921A (ko) 암을 치료하기 위한 방법 및 조합 요법
JP7206203B2 (ja) がんの重症度を評価するためのｔｉｍ－３
Huang et al. Cluster of differentiation 24 expression is an independent prognostic factor of adverse outcome in cervical carcinoma
Zhang et al. Gastrointestinal (Non-colorectal) Cancer
WO2023083863A1 (en) Method for monitoring the response to neoadjuvant therapy for breast cancer
Ahmed Shameem et al. Expression of proliferating cell nuclear antigen and deoxyribonucleic acid value in renal cell carcinoma: correlation with different histopathological parameters and patient survival
Stål et al. Overexpression of c-erbB-2 protein and locoregional recurrence in node-positive breast cancer
KR20230075765A (ko) 동시항암방사선치료를 받은 비소세포성 폐암 환자의 방사선 폐렴 중증도의 예측 방법
CN114480634A (zh) 半乳糖凝集素-1作为一种生物标志物在诊断肿瘤耐药中的应用
KR20220149336A (ko) 부인암 pdx 모델에 대한 성공 예측 방법
US20150355185A1 (en) Using galectin-binding carbohydrates as predictors of melanoma progression and metastasis

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application